CIK 0001645460 · Non-accelerated filer<br>Smaller reporting company
Cue Biopharma, Inc.
Sign in to watch- Ticker
- CUE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473324577
- Phone
- 617-949-2680
- Business address
- 100 CHESTNUT STREET, SUITE 300, SOMERVILLE, MA, 02143
- Former names
- Imagen Biopharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $389,304
- in 3 filings
Net −$389,304. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 20 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-01 | Lin Shao-Lee Chief Executive Officer | Purchase · Common Stock Warrants (Right to Buy) | +45,453 | 45,453 | ||
| 2026-05-30 | Camardo Daniel A. Director | Grant or award · Stock Option (Right to Buy) | +1,626 | 1,626 | ||
| 2026-05-30 | Meehan Viola Mong Director | Grant or award · Stock Option (Right to Buy) | +1,626 | 1,626 | ||
| 2026-05-03 | Lin Shao-Lee CHIEF EXECUTIVE OFFICER | Grant or award | +327,537 | 327,537 | ||
| 2026-05-03 | Lin Shao-Lee CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (right to buy) | +655,074 | 655,074 | ||
| 2026-04-09 | Sandercock Colin SVP, GENERAL COUNSEL | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2026-04-09 | Warren Lucinda CHIEF BUSINESS OFFICER | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2026-04-09 | Baker Daniel G. CHIEF DEVELOPMENT OFFICER | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2026-01-02 | Kiener Peter A Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2026-01-02 | Broadfoot Jill Marie Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2026-01-02 | Morich Frank Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2026-01-02 | Garzone Pamela Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2026-01-02 | Verheyen Patrick Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2026-01-02 | Sarraf Pasha Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2025-12-30 | Sarraf Pasha Director | Purchase | +4,229 | $0.31 | $1K | 4,229 |
| 2025-12-30 | Sarraf Pasha Director | Purchase | +77,148 | $0.30 | $23K | 81,377 |
| 2025-12-30 | Sarraf Pasha Director | Purchase | +86,947 | $0.32 | $28K | 168,324 |
| 2025-12-30 | Sarraf Pasha Director | Purchase | +78,116 | $0.31 | $24K | 246,440 |
| 2025-12-30 | Sarraf Pasha Director | Purchase | +77,417 | $0.30 | $23K | 323,857 |
| 2025-12-03 | Sandercock Colin SVP, GENERAL COUNSEL | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 |
Page 3 of 17 · 323 trades